Drug Profile


Alternative Names: ACU-NCT-001; ATV-02; N-chlorotaurine - Manhattan Pharmaceuticals; NCT - Pathogenics

Latest Information Update: 21 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Innsbruck
  • Developer Medical University of Vienna; OPKO Health; Pathogenics
  • Class Alkanesulfonic-acids; Antibacterials; Antifungals
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Acanthamoeba infections; Infectious conjunctivitis; Otitis externa; Sinusitis; Skin ulcer

Most Recent Events

  • 25 Feb 2008 Antimicrobial data from a preclinical trial in acanthamoeba infections released by OPKO Health and Pathogenics Inc.
  • 12 Jul 2007 Opko Corporation is now called Opko Health
  • 27 Mar 2007 eXegenics has merged with Acuity Pharmaceuticals to form Opko Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top